Payment overview · 2025
General Payments
$191.91
10 reported records · 7 companies
Healthcare provider profile · identity verified
William J Crowley, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PORT LAVACA, TX · NPI 1609870161
Verified facts
What the public records show
CMS Open Payments records show William J Crowley, D.O. received $191.91 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.49 | 20.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.74 | 18.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.04 | 17.7% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $31.48 | 16.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.14 | 9.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.52 | 9.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.50 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.91 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $31.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 475 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 142 |
| Lisinopril | Lisinopril | 330 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 83 |
| Tramadol Hcl | Tramadol Hcl | 306 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 74 |
| Losartan Potassium | Losartan Potassium | 257 | 69 |
| Alprazolam | Alprazolam | 230 | 51 |
| Furosemide | Furosemide | 224 | 57 |
| Gabapentin | Gabapentin | 220 | 66 |
| Potassium Chloride | Potassium Chloride | 196 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 42 |
| Omeprazole | Omeprazole | 172 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 42 |
| Metformin Hcl | Metformin Hcl | 154 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 45 |
| Simvastatin | Simvastatin | 139 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 36 |
| Glipizide | Glipizide | 114 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 109 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 26 |
| Torsemide | Torsemide | 90 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 18 |
| Allopurinol | Allopurinol | 81 | 23 |
| Spironolactone | Spironolactone | 79 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 24 |
| Ozempic | Semaglutide | 70 | 13 |
| Mirtazapine | Mirtazapine | 68 | 14 |
| Cephalexin | Cephalexin | 67 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | suppressed |
| Meloxicam | Meloxicam | 67 | 20 |
| Trazodone Hcl | Trazodone Hcl | 67 | 17 |
| Eliquis | Apixaban | 65 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 15 |
| Januvia | Sitagliptin Phosphate | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 14 |
| Prednisone | Prednisone | 53 | 38 |
| Alendronate Sodium | Alendronate Sodium | 51 | 14 |
| Pregabalin | Pregabalin | 51 | 16 |
| Sertraline Hcl | Sertraline Hcl | 50 | 15 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Finasteride | Finasteride | 44 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 17 |
| Metformin Hcl Er | Metformin Hcl | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 17 |
| Lorazepam | Lorazepam | 43 | 11 |
| Levetiracetam | Levetiracetam | 42 | 13 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Carvedilol | Carvedilol | 38 | 11 |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 12 |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 27 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 15 |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 13 |
| Austedo | Deutetrabenazine | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 26 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Metolazone | Metolazone | 22 | 11 |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Valsartan | Valsartan | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Trokendi Xr | Topiramate | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.91 · 10 records | Novo Nordisk Inc | AREXVY, Azstarys, BREZTRI, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, SHINGRIX, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error